Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy.
Gemfibrozil therapy alone can induce severe myopathy and rhabdomyolysis. This catastrophic complication had been frequently reported in renal failure patients. Dosage reduction is therefore compulsory in patients with compromised renal function, no matter which type of renal replacement therapy they receive. This study's patient clearly demonstrates that gemfibrozil can induce severe rhabdomyolysis, even in patients receiving CVVH, if the dosage is not properly adjusted.
Yen
Tzung-Hai
TH
Division of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan.
Chang
Chiz-Tzung
CT
Wu
Mai-Szu
MS
Huang
Chiu-Ching
CC
D000208:Acute Disease; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D015248:Gemfibrozil / Q000009:adverse effects*; D006440:Hemofiltration; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D010195:Pancreatitis / Q000150:complications / Q000628:therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy*; D012206:Rhabdomyolysis / Q000139:chemically induced*
D000960:Hypolipidemic Agents; D015248:Gemfibrozil